article thumbnail

American Cancer Society, Teva Pharmaceuticals launch coalition to advocate for equity through digital health

Fierce Healthcare

American Cancer Society, Teva Pharmaceuticals launch coalition to advocate for equity through digital health. agliadkovskaya. Mon, 05/23/2022 - 16:43

article thumbnail

Industry Voices—How the pharmaceutical industry can turn the tide on mental health

Fierce Healthcare

Industry Voices—How the pharmaceutical industry can turn the tide on mental health. pminemyer. Fri, 05/13/2022 - 10:15

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BCBS of Vermont sues Teva Pharmaceuticals over marketing for its MS drug Copaxone

Fierce Healthcare

BCBS of Vermont sues Teva Pharmaceuticals over marketing for its MS drug Copaxone. fdiamond. Tue, 08/23/2022 - 15:07

article thumbnail

2023 State Legislative Action to Lower Pharmaceutical Costs

NASHP

The post 2023 State Legislative Action to Lower Pharmaceutical Costs appeared first on NASHP. Updated January 20, 2023 Explore the status of state legislation to address prescription drug costs using the map and chart below.

article thumbnail

Effect of pharmaceutical innovation on longevity

Healthcare ECONOMIST

2022) measures the relationship between pharmaceutical innovation and longevity. Both figures are well below per capita GDP in the respective regions, suggesting that, overall, pharmaceutical innovation was highly cost-effective. International Health Care Systems Pharmaceuticals InnovationUsing data from 2006-2018 across 26 high-income countries, Lichtenberg et al.

article thumbnail

2021 State Legislative Action to Lower Pharmaceutical Costs

NASHP

2021 State Legislative Action to Lower Pharmaceutical Costs Updated September 22, 2021. Find the status of state legislation to address prescription drug costs below. Use the category button to search by type of legislation and roll over a state to view its pending drug legislation.

article thumbnail

Relative importance of pharmaceuticals on health outcomes: 1990-2015

Healthcare ECONOMIST

Is it new surgical techniques, better diagnostics, improved medical devices, or new pharmaceuticals? Based on physicians responses, across all 8 diseases , pharmaceuticals had the largest impact on health. Across all 8 diseases 56% of the relative value came from pharmaceuticals.

article thumbnail

Many Hospitals Receiving Discounted Drugs May Not Offer Patients Pharmaceutical Assistance

Bill of Health

Section 340B of the Public Health Service Act requires that pharmaceutical manufacturers give discounts on specified outpatient drugs to certain covered entities who typically serve low-income or otherwise underserved patients, including hospitals and clinics.

article thumbnail

Pharmaceutical Manufacturers Ask EDVa to Allow Cost-Sharing Under the AKS

Healthcare Law Blog

Pharmaceutical manufacturers are challenging the breadth of the Federal Anti-Kickback Statute (“AKS”) in federal court, arguing that the government is harming the very vulnerable patients it aims to serve by prohibiting cost-sharing subsidies for life-saving oncology drugs.

article thumbnail

OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidies

Healthcare Law Blog

22-19 (the “Opinion”), which limits the ability of pharmaceutical manufacturers to offer cost-sharing subsidies to Medicare Part D (“Part D”) beneficiaries via 501(c)(3) charities without running afoul of the Federal Anti-Kickback Statute (the “AKS”).

article thumbnail

Proposed FDA Rules Could Be Game Changers for the Pharmaceutical Supply Chain

Holland & Knight

Shannon Britton Hartsfield

article thumbnail

Decolonizing the Pandemic Treaty Through Vaccine Equity

Bill Of Health

The Doha Declaration , enacted in 2001, attempts to address global inequities stemming from intellectual property protections by allowing countries to grant compulsory licenses for the production of pharmaceuticals for international exports.

article thumbnail

The Pandemic Treaty and Intellectual Property Sharing: Making Vaccine Knowledge a Public Good 

Bill Of Health

Once that knowledge was transferred to the private sector, these private pharmaceutical companies became the holders of the knowledge, related intellectual property, and regulatory dossiers that are needed to bring the products to market. By Ellen ‘t Hoen.

article thumbnail

Being an Adult in the Face of Omicron

Bill Of Health

As publicly traded entities, pharmaceutical companies are under legal obligations to maximize shareholder value , not to act in the interests of public health. By Jennifer S.

article thumbnail

Who Has a Duty to Protect Your Health? The Answer May Surprise You

Bill Of Health

By Jennifer S. One of the most frightening aspects of the ongoing COVID-19 pandemic has been the lack of a recognized and trusted source of health and safety information.

Doctors 276
article thumbnail

CeBIL Annual Symposium 2021 – Orphan Drug Innovation: Needs and Priorities

Bill Of Health

However, since each disease affects less than one person in every 2,000, the pharmaceutical industry has traditionally been reluctant to invest in research and development connected to such illnesses given the small market.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Government Pharmaceutical Development to Address High Prices: Challenges Ahead. Kesselheim aging Ameet Sarpatwari Beatrice Brown FDA Health Law Policy Patient Care Pharmaceuticals PORTAL Round-Up Professional Regulation aducanumab Alzheimer's disease cancer generic drugs

article thumbnail

Washington Psilocybin Bill Would Legalize Supported Adult Use

Bill Of Health

By Mason Marks. On Tuesday, Washington State legislators filed SB 5660 , a bill that would legalize the supported adult use of psilocybin by people 21 years of age and older.

Law Firms 284
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Reimagining Pharmaceutical Market Exclusivities: Should the Duration of Guaranteed Monopoly Periods Be Value Based? Ameet Sarpatwari , Beatrice Brown , Alexander Egilman , Aviva Wang, and? Aaron S. Kesselheim.

article thumbnail

The Government Needs to Construct On, Not Off, Ramps to Combat the Latest Wave of COVID

Bill Of Health

By Jennifer S. Over the past two weeks, the news coming in about the spread of COVID-19 has been eerily familiar.

article thumbnail

Book Review: ‘Drugs and the FDA: Safety, Efficacy, and the Public’s Trust’ by Mikkael A. Sekeres

Bill of Health

Bioethics Biotechnology FDA FDA in the 21st Century Conference Matthew Chun Medical Safety Pharmaceuticals access to medicine Book Review drug law drug regulation Patient autonomy pharmaceuticalBy Matthew Chun.

article thumbnail

How Social Movements Have Facilitated Access to Abortion During the Pandemic

Bill Of Health

By Rachel Rebouché. Before the end of 2021, the U.S. Food and Drug Administration (FDA) will reconsider its restrictions on medication abortion.

article thumbnail

FDA’s 2022 Drug Approvals

Healthcare ECONOMIST

HC Statistics Pharmaceuticals Regulation Biosimilars FDA FDA ApprovalsThe year 2022 was a good, but perhaps not great year for innovation.

article thumbnail

Bill of Health’s Top 10 Posts of 2022

Bill of Health

Bioethics Biotechnology Disability Health Law Policy Petrie-Flom Center Pharmaceuticals Public Health coronavirus coronavirus pandemic COVID-19 COVID19 microdosing nate holdren poplar psilocybin social murderBy Chloe Reichel.

article thumbnail

“40% of generic drugs have just one manufacturer”

Healthcare ECONOMIST

Current Events Pharmaceuticals Generic drugs GenericsThat is part due to the squeeze on generic drug pricing from group purchasing organizations and others. This 60 Minutes report is interesting.

article thumbnail

Should Vaccinating Children Off-Label Against COVID-19 Be Universally Prohibited?

Bill Of Health

By Govind Persad , Patricia J. Zettler , and Holly Fernandez Lynch. As children are experiencing the highest rates of COVID-19 in many states , can efforts to universally preclude vaccination of those under 12 until the U.S.

article thumbnail

Addressing IP Barriers in the Context of a Pandemic Treaty

Bill Of Health

This post was originally published on the Verfassungsblog as part of our joint symposium on international pandemic lawmaking. By Paul Ogendi.

article thumbnail

Legal and Ethical Analysis of Court-Ordered Ivermectin Treatment for COVID-19

Bill Of Health

Bioethics FDA Featured Health Law Policy Jennifer Bard Judicial Opinions Medical Safety Off-Label Use Patient Care Pharmaceuticals Professional Regulation Public Health Autonomy coronavirus coronavirus pandemic COVID-19 COVID19 ivermectin jennifer bard Ohio public health research ethics

Doctors 285
article thumbnail

Dr. J. Allen Meadows: How digital inhalers have led to more informed treatment discussions in my practice

Health Care Dive

Allen Meadows worked with Teva Pharmaceuticals to share his experience with the Digihaler® family of inhalers and accompanying platforms

article thumbnail

Inflation Reduction Act already impacting life science R&D decisions

Healthcare ECONOMIST

That is the takeaway according to a November-December 2022 survey by PhRMA of 25 large pharmaceutical manufacturers. Pharmaceuticals Public PolicyAmong respondents, it was clear the IRA price setting provisions are already impacting, and are expected to have a growing impact on, R&D plans moving forward: • 78% expect to cancel early-state pipeline projects. • 63% said they expect to shift R&D investment focus away from small molecule medicines. •

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Trends in drug revenue among major pharmaceutical companies: A 2010-2019 cohort study. Kesselheim Ameet Sarpatwari Beatrice Brown FDA Health Law Policy Pharmaceuticals PORTAL Round-Up PORTALAmeet Sarpatwari , Beatrice Brown , Alexander Egilman , and? Aaron S. Kesselheim.

Medicare 139
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy 

Bill of Health

The selections feature topics ranging from an examination of Park doctrine prosecutions of executives of pharmaceutical and medical device companies, an analysis of patent thickets covering biologic drugs, and a discussion of product hopping strategies among manufacturers of inhalers.

article thumbnail

Promoting Vaccine Equity

Bill Of Health

By Ana Santos Rutschman. The COVID-19 pandemic has brought into sharp relief longstanding equity problems surrounding the allocation of newly developed vaccines against emerging pathogens.

article thumbnail

The Age of Orphans

Bill Of Health

At the start of the 2020s, as the types of pharmaceutical innovations to launch became much more specialist, the companies behind these launches also evolved. Join the author today for the 2021 CeBIL Symposium. Register here! By Sarah Rickwood. The 2020s are the age of orphan medicines.

Doctors 161
article thumbnail

Is Preemption the Cure for Healthcare Federalism’s Restrictions on Medication Abortion?

Bill of Health

As a result, the question of whether states can restrict or ban pharmaceuticals approved by the U.S. The FDA achieves its congressionally charged mission , in part, through its gatekeeping function as the primary regulator of pharmaceuticals in the United States.

article thumbnail

Falling Revenue Means Pharmacies in Italy Aren’t Keeping up with Other EU Countries

Bill of Health

In 2021, the total revenue of Italian pharmacies dropped by 4% compared to 2015, despite Italy being the fifth largest country in the EU for pharmaceutical expenditures. By Gianluca Ceci and Sarah Gabriele.

article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill Of Health

Kesselheim Ameet Sarpatwari Beatrice Brown Health Law Policy Pharmaceuticals PORTAL Round-Up Vaccines PORTALAmeet Sarpatwari , Beatrice Brown , Aviva Wang, and? Aaron S. Kesselheim.

Medicare 174
article thumbnail

Cigna-owned Express Scripts taps new president

Healthcare Dive

Previously, Adam Kautzner led pharmaceutical and retail network contracting and drug sourcing as vice president of supply chain for the PBM and Accredo Pharmacy

article thumbnail

What Democrats’ Drug Pricing Plan Means for Consumers

Bill Of Health

The plan places a $2,000 cap on out-of-pocket spending on pharmaceuticals for seniors enrolled in Medicare Part D, which currently covers 48 million people, or 77% of all Medicare beneficiaries. As it stands, Medicare has no cost-sharing cap on pharmaceuticals. By Cathy Zhang.

Medicare 161
article thumbnail

Monthly Round-Up of What to Read on Pharma Law and Policy

Bill of Health

Kesselheim Abortion Ameet Sarpatwari Intellectual Property Pharmaceuticals PORTAL Round-Up Publications antitrust Drug Pricing medication abortion patent thicket PORTALBy  Ameet Sarpatwari , A viva Wang , and  Aaron S. Kesselheim.

article thumbnail

The Evolution of a Patient Ambassador – Learning from Stacy Hurt

Health Populi

Tallying up the years between her working in physician practice management and the pharmaceutical sector, as well as time spent in health advocacy, “I’ve been 25 years in health care,” Stacy calculated.

article thumbnail

Impact of medication cost-sharing on adherence, clinical outcomes, health care utilization, and costs

Healthcare ECONOMIST

Health Insurance Pharmaceuticals Adherence Cost Cost sharing HCRU Medication SLR Systematic Literature ReviewThis is the paraphrased title of a paper by Fusco et al. 2023).

article thumbnail

How much do orphan drugs cost?

Healthcare ECONOMIST

HC Statistics Pharmaceuticals Public Policy Rare disease Orphan DrugsThe answer is provided in a recent white paper by Pearson, Schapiro and Pearson (2022). They use IQVIA data through 2020 across 389 drugs treating 1.8 million individuals.